125 related articles for article (PubMed ID: 24950369)
1. CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.
Olagunju A; Schipani A; Siccardi M; Egan D; Khoo S; Back D; Owen A
Pharmacogenet Genomics; 2014 Sep; 24(9):459-63. PubMed ID: 24950369
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
3. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
Schipani A; Egan D; Dickinson L; Davies G; Boffito M; Youle M; Khoo SH; Back DJ; Owen A
Antivir Ther; 2012; 17(5):861-8. PubMed ID: 22477766
[TBL] [Abstract][Full Text] [Related]
5. Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.
Zhang X; Tierney C; Albrecht M; Demeter LM; Morse G; DiFrancesco R; Dykes C; Jiang H; Haas DW
Ther Drug Monit; 2013 Apr; 35(2):209-16. PubMed ID: 23503447
[TBL] [Abstract][Full Text] [Related]
6. Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.
Mpeta B; Kampira E; Castel S; Mpye KL; Soko ND; Wiesner L; Smith P; Skelton M; Lacerda M; Dandara C
Pharmacogenomics; 2016 May; 17(7):679-90. PubMed ID: 27142945
[TBL] [Abstract][Full Text] [Related]
7. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
Hartkoorn RC; Kwan WS; Shallcross V; Chaikan A; Liptrott N; Egan D; Sora ES; James CE; Gibbons S; Bray PG; Back DJ; Khoo SH; Owen A
Pharmacogenet Genomics; 2010 Feb; 20(2):112-20. PubMed ID: 20051929
[TBL] [Abstract][Full Text] [Related]
8. Influence of SLCO1B1 polymorphisms on lopinavir C
Dragović G; Dimitrijević B; Kušić J; Soldatović I; Jevtović D; Olagunju A; Owen A
Br J Clin Pharmacol; 2020 Jul; 86(7):1289-1295. PubMed ID: 32022294
[TBL] [Abstract][Full Text] [Related]
9. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
10. Genomewide Association Study of Simvastatin Pharmacokinetics.
Mykkänen AJH; Taskinen S; Neuvonen M; Paile-Hyvärinen M; Tarkiainen EK; Lilius T; Tapaninen T; Backman JT; Tornio A; Niemi M
Clin Pharmacol Ther; 2022 Sep; 112(3):676-686. PubMed ID: 35652242
[TBL] [Abstract][Full Text] [Related]
11. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.
López Aspiroz E; Cabrera Figueroa SE; Iglesias Gómez A; Valverde Merino MP; Domínguez-Gil Hurlé A
Clin Drug Investig; 2015 Jan; 35(1):61-6. PubMed ID: 25391550
[TBL] [Abstract][Full Text] [Related]
12. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
Luzum JA; Theusch E; Taylor KD; Wang A; Sadee W; Binkley PF; Krauss RM; Medina MW; Kitzmiller JP
J Cardiovasc Pharmacol; 2015 Jul; 66(1):80-5. PubMed ID: 26164721
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.
Schipani A; Siccardi M; D'Avolio A; Baietto L; Simiele M; Bonora S; Rodríguez Novoa S; Cuenca L; Soriano V; Chierakul N; Saguenwong N; Chuchuttaworn C; Hoskins JM; Dvorak AM; McLeod HL; Davies G; Khoo S; Back DJ; Di Perri G; Owen A
Antimicrob Agents Chemother; 2010 Dec; 54(12):5242-50. PubMed ID: 20921307
[TBL] [Abstract][Full Text] [Related]
15. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
BMC Med Genet; 2014 Jul; 15():76. PubMed ID: 24986243
[TBL] [Abstract][Full Text] [Related]
16. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
[TBL] [Abstract][Full Text] [Related]
17. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
ter Heine R; Van Waterschoot RA; Keizer RJ; Beijnen JH; Schinkel AH; Huitema AD
J Pharm Sci; 2011 Jun; 100(6):2508-15. PubMed ID: 21491455
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
Khaykin P; Kotzerke P; Stephan C; Nisius G; Bickel M; Haberl A; Stürmer M; Kurowski M; Brodt R; von Hentig N
Ther Drug Monit; 2014 Apr; 36(2):192-201. PubMed ID: 24632753
[TBL] [Abstract][Full Text] [Related]
19. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
20. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Ulvestad M; Skottheim IB; Jakobsen GS; Bremer S; Molden E; Asberg A; Hjelmesæth J; Andersson TB; Sandbu R; Christensen H
Clin Pharmacol Ther; 2013 Mar; 93(3):275-82. PubMed ID: 23361102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]